Spexis Appeals Suspension of its Shares on SIX Exchange

Spexis AG, the clinical-stage biopharmaceutical firm known for its work in macrocycle therapeutics, has initiated an appeal against the recent decision by SIX Exchange Regulation AG (SER) to suspend trading of its shares starting June 3, 2024. The appeal follows a granted extension to publish its audited 2023 annual report by July 31, 2024, while unaudited accounts were released on May 31, 2024.

According to Spexis, the suspension is unwarranted as the company has complied with the Issuers Committee’s conditions to maintain trading by publishing its unaudited annual report. Spexis argues that SER has overstepped its authority and, as part of the appeal, has requested the resumption of trading as an interim measure.